Skip to main content

Table 2 Univariate analysis of factors influencing the acquisition of carbapenemase-producing enterobacteriaceae

From: Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011–2016) case-control study

Variables

CPE (%)

Controls (%)

ORa

P value

Ward of hospital stay

Medicine

7 (6.5%)

100 (93.5%)

Ref.b

 

High-risk

37 (77.1%)

11 (22.9%)

48.0 (17.3–133.2)

< 0.001

Surgery

14 (17.5%)

66 (82.5%)

15.8 (6.5–38.4)

< 0.05

LOSc

< 20 days

31 (16.9%)

152 (83.1%)

Ref.b

 

≥ 20 days

27 (51.9%)

25 (48.1%)

5.3 (2.7–10.3)

< 0.001

Admission origin

Home

36 (18.8%)

155 (81.2%)

Ref.b

 

Non-Austrian hospital

12 (85.7%)

2 (14.3%)

25.8 (5.5–120.5)

< 0.001

Austrian hospital

10 (33.3%)

20 (66.7%)

12 (2.2–64.3)

ns

Hospital admission in the previous yeard

none

18 (10.8%)

148 (89.2%)

Ref.b

 

yes

40 (58.0%)

29 (42.0%)

11.4 (5.7–22.4)

< 0.001

Surgical interventions

none

49 (22.5%)

169 (77.5%)

Ref.b

ns

yes

9 (52.9%)

8 (47.1%)

3.9 (1.4–10.6)

< 0.001

Mechanical ventilation (MV)

none

33 (17.6%)

154 (82.4%)

Ref.b

 

yes

25 (52.1%)

23 (47.9%)

5.1 (2.6–10.0)

< 0.001

Central vascular catheter (CVC)

none

19 (12.7%)

131 (87.3%)

  

yes

39 (45.9%)

46 (54.1%)

5.8 (3.1–11.1)

< 0.001

Presence of co-morbidity (CCIe)

< 4

43 (22.5%)

148 (77.5%)

  

≥4

15 (34.1%)

29 (65.9%)

1.8 (0.8–3.6)

ns

Carbapenem exposuref

none

46 (79.3%)

174 (98.3%)

Ref. b

 

yes

12 (20.7%)

3 (1.7%)

15.1 (4.1–55.9)

< 0.001

Antimicrobial therapy >  10 daysf

none

27 (46.6%)

144 (29.3%)

Ref. b

 

>  10 days

14 (24.1%)

4 (2.3%)

18.6 (5.7–61.0)

< 0.001

<  10 days

17 (29.3%)

29 (16.4%)

5.9 (1.7–21.1)

ns

Contact with healthcare system of high-risk countryf,g

none

39 (19.0%)

166 (81.0%)

Ref. b

 

yes

19 (63.3%)

11 (36.7%)

6.8 (2.9–15-5)

<  0.001

  1. aOR: Odds ratio, bRef.: Reference category, cLOS: Length of stay, d in any hospital, eCCI: Charlson comorbidity index, f 90 days before VGH admission, g Healthcare system of countries of high or unknown carbapenem-resistant enterobacteriaceae prevalence.